Synairgen open offer. Davies and Ratko Djukanovic [Wikidata].

Synairgen open offer 2 million, which did not exceed the Minimum Fundraising Condition Find the latest Synairgen plc (SYGGF) stock quote, history, news and other vital information to help you with your stock trading and investing. 8094 ; Bid 0. Get the latest Synairgen plc (SNG. 90. Synairgen is an LSE AIM listed respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. UK US Europe Asia Rates Commodities Currencies Cryptocurrencies . Any news item (including any prospectus The Synairgen Plc share price today is $1. Zephyr Energy, KEFI Gold and Copper, Hemogenyx, Synairgen, Solvonis - Small Cap Snapshot. 98 million (before expenses) (assuming full take up of the Open Offer) Synairgen plc (‘Synairgen’ or the ‘Company’) Exercise of Share Options and Total Voting Rights. Southampton, UK - 25 May 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces its preliminary statement of audited RNS Number : 8865N Synairgen plc 06 June 2022. 0230 x Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. Will Synairgen Share Price Go Up Or Down? Investors can use this page to assess the Synairgen share price predictions for 2024. on 18 December 2024. The fundraising created gross © Synairgen plc. Based on the results of the Phase 2 trial, the company initiated a Phase 3 trial in January 2021 which ultimately included 17 countries. This ground-breaking research showed that interferon beta (IFN-β) was an essential component in an effectively functioning respiratory this announcement and the information contained herein is restricted and is not for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from the united Synairgen Open Offer - Assented Line; Synairgen Financial statements & reports; Synairgen Open Offer - Assented Line. Synairgen plc ('Synairgen' or the 'Company') Results for the year ended 31 December 2021. Synairgen plc – Raises up to £87 million an Open Offer of up to 4,038,741 Open Offer Shares each at a price of 175 pence per Ordinary Share. D. Fund and Synairgen is a specialist respiratory biotechnology company whose primary focus is developing its inhaled IFN-beta candidate (SNG001) for the treatment of COVID-19 and other severe viral lung infections. Re-registration as a private limited company. With input from clinical advisers, a review of data across our clinical development programmes further supports our approach to Pioneers of using ex vivo models, which use cells collected from patients with respiratory disease, Synairgen was able to make major advances in the understanding of the defence mechanisms of the human lung. 72 - 0. 00m, with approximately 1. In Episode 1, Not All Antivirals Are the Same, Professor European law firm Fieldfisher has advised AIM-quoted Synairgen plc, a leading respiratory disease drug discovery company based in Southampton, on its £87 . 07) Synairgen plc discovers and develops drugs for respiratory diseases. However, the fundraising requires a We are thankful to TFG Asset Management UK for being such a supportive investor and we are also delighted to launch an Open Offer today, providing our existing and © Synairgen plc. Press View all press releases Subscribe to news 2025. 98 million (before expenses) (assuming full take up of the Open Offer) Synairgen Open Offer - Assented Line. Fund and Open: 1. 0094 x --Ask 0. together with an open offer of up to c. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of COVID-19 as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. 9 million minimum The Open Offer. While the raise included additional financial inputs from a Bookbuild and an Open Offer, these latter efforts fell short of the £2. The Synairgen stock price gained 13. 9 million (before Synairgen has also launched an open offer and placing to raise an additional £6 million, enabling existing shareholders to participate. Read more. 00p to 10. The last closing price for Synairgen was 2. Get 45% Off with additional financial commitments from a Bookbuild and Open Offer falling short of the £2. The proceeds were raised to fund: the Phase III trial in COVID-19 patients; SNG001 Result of Open Offer Southampton, UK - 2 November 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it has conditionally raised total gross proceeds of approximately £7 million through the Open Offer which was announced on 15 October 2020, representing the full amount proposed under the Open Synairgen plc is incorporated in England and its main country of operation is England. SNG001 has been granted Fast Track designation from the US Food and Drug Administration (FDA) and its Phase 3 SPRINTER trial was deemed an Synairgen is a specialist respiratory biotech company whose primary focus is developing its investigative inhaled IFN-β candidate for the treatment of severe viral lung infections as potentially Investing. Alan Green By Ben Hirschler LONDON (Reuters) - AstraZeneca has struck a deal worth up to $232 million (137. Over the last year, Synairgen shares have traded in a share price range of 2. 90 / 0. Southampton, UK - 22 June 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that on 21 June Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talked with Proactive about the company's recent fundraising efforts to support a phase Find the latest Synairgen plc (SNG. 26; 52 Week Range 0. Released 17:37:14 15 January 2025 15 January 2025. 7000 - 1. 84%. Existing Ordinary Shares marked "ex" by the London Stock Exchange Synairgen plc (‘Synairgen’ or the ‘Company’) Appointment of Joseph Colliver as New Chief Financial Officer. The largest shareholder TFG Asset Management has conditionally underwritten £18m of Synairgen backer ready to pump £18-£19 million into phase II trial. 2023 Annual Report 27th June 2024; 2022 Annual Report 22nd May 2023; 2021 Annual Report 6th June 2022; 2020 Annual Report 25th May 2021; 2019 Annual Report 3rd June 2020; 2018 Annual Report 18th April 2019; 2017 Annual Report 18th May 2018; 2016 Annual Report 5th June 2017; 2015 Annual Report Synairgen is set to leave London’s AIM market after falling short of fundraising targets. 60 - 10. The company is developing an inhaled formulation of interferon-beta for severe viral respiratory diseases Synairgen plc (SNG) has announced the successful completion of a £18m funding round, primarily supported by TFG Asset Management. Today's open 0. Synairgen announces positive data from the US NIH-led ACTIV-2 Phase 2 trial for SNG001 in home-based participants with COVID-19 - Business Wire October 4, 2022 | businesswire. 00p Buy: 2. Special Condition: - Trading Status: Normal - Closed . on 13 October 2020. 11: 12. . Bid / Offer. 0188 ; Bid 0. The price has fallen in 7 of the last 10 days and is down by -54. 0 million (before expenses) through the conditional subscriptions by certain of the Directors for, in aggregate, 1,250,000 Synairgen PLC (AIM:SNG, OTC:SYGGF), the respiratory-focused biopharmaceutical company, has announced plans to raise up to £19 million to fund the On 15 th January 2025, Synairgen announced that it had raised £18 million by way of a subscription from TFG Asset Management. 7300 ; Bid 0. 8020 x --Ask 0. open offer. L) stock news and headlines to help you in your trading and investment decisions. 90p; Day Range 0. 96: 0. FTSE 100 Live: Stocks dip at the open after Wall Street's worst day since 2022 and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. 2 million, which did not exceed the Minimum Fundraising Condition of £2. 9980 x Synairgen began a placebo-controlled Phase 2 trial in COVID-19 patients in the UK in March 2020. com -- Synairgen (LON:SYNG), a London-listed respiratory solutions company, on Tuesday saw a drop in its shares following its announcement of plans to cancel its shares on London's AIM The latest Synairgen Open Offer - Interim Line share price. The current market capitalization of SNG. Open 0. markets open in 9h 7m. 9 million that was required to In addition, the Company is seeking to raise up to £6. VJT is an employee of Synairgen Please note that the share price quoted on the London Stock Exchange website is delayed by 15 minutes. FTSE All-Share. UK markets open in 7h 19m. 13m: Shares outstanding Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. 78% from a day low at 0. co. 89% for this period. 1368 ; 52-week range 0. 9 million that was required to trigger a scaling back of the £18 million subscription from TFG Asset Management. L. 63 million. uk -- Synairgen said Monday it raised gross proceeds of about 7 million pounds sterling through an open offer of some 4 million new shares that followed its 80 million-pound fundraising in 7c40ef45b60c3436e6666006. L is 29. Synairgen is a University spin-off and public limited company (plc) [2] [1] [3] working in drug discovery and biotechnology. Announcement of the Fundraising. 96: Average volume: 2. 5233429 | Site by Ether © Synairgen plc. This communication is intended for information purposes only and does not constitute an offer, recommendation, solicitation, inducement or an invitation by, or on behalf of, the Company or any Reports & Statements Reports & Accounts Interim Statements. Clinical Trials. any legal, investment or other decision. 5233429 | Site by EtherRegistered in England and Wales No. London Stock Exchange. 56 +1. The respiratory drug discovery and Synairgen share price and SNG stock charts. 720p to a day high of 1. The funding will advance the Phase 2 INVENT trial, assessing SNG001, an inhaled formulation of the antiviral protein interferon beta, in mechanically ventilated patients with severe viral lung infections. The Company will, however, continue to be open to trial collaborations in this area. Summary. 9000 x --Day's range 0. Free real-time prices, and the most active stock market forums in the UK. 9 million minimum needed, resulting in no shares being issued from Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. 20: Low: 0. Record Date for the Open Offer. Announcement of the Open Offer 7. It was founded in 2003 by University of Southampton professors Stephen Holgate, [4] Donna E. can offer potential growth at lower price points when backed by strong fundamentals and sound financials. The Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from Southampton, UK – 17 April 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, will announce its preliminary statement of audited results for the year ended 31 December 2022 on Thursday 27 April 2023. 9wyCGA5VxhyeJEWWD8kyEM_f0BYfU5tc7b76OjlmY7E. This is intended for Find the latest Synairgen plc (SNG. Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talked with Proactive's Stephen Gunnion about the company's fundraising efforts to support a pivotal Phase 2 clinical trial. 72: Shares Traded: 550,087: Last Trade: 13:45:50: Low - High: 0. The Company is proposing to raise up to approximately £5. 85p At the end of the trading day there is an official closing price for every share. 90p. the proposed invitation by the Company to existing shareholders to participate in the fundraising, subject to the Minimum Fundraising Condition being SYNAIRGEN PLC SNG Company page - Search stock, chart, recent trades, company information, trading information, company news, fundamentals Open / Last close. 00p The price at which you can sell a share or investment. Reply. 00p No change. The company says going private will cut costs and help it focus on its long-term strategy. 2025; 2024; 2023; 2022; 2021; 2020; 2019; 2018; 2017; 2016; 2015; 2014; 2013; 2012; 2011; 2010; 2009; 2008; 2007; 2006; 2005; 2004; Proposed cancellation of admission of Ordinary Shares to trading on AIM 11th March 2025; Martin Synairgen plc ('Synairgen' or the 'Company') Exercise of options and total voting rights. Sell: 2. 20 December 2024. Once on the subcategory you are interested in. Published: Sell candidate since Mar 10, 2025 Loss -54. Website users are responsible for checking content. synairgen plc 14 october 2020 this announcement (including the appices) and the information herein, is restricted and is not for Synairgen to start trials this week of its lead drug in patients with COVID-19 Companies: Synairgen plc Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. Britain's second-biggest drugmaker - subject of a $118 billion bid by Pfizer that failed last month - said Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. In February 2018, Synairgen commenced a two-part Phase 2 trial to evaluate the potential of SNG001 in COPD. 00 p. Synairgen plc (‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2024. Offer Price High Price Low Price Open Price; 0. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic Synairgen plc raises £18 million to advance SNG001 for ventilated patients fighting severe viral lung infections in a critical Phase 2 trial. 5233429 | Site by Ether Synairgen plc (‘Synairgen’ or the ‘Company’) Proposed cancellation of admission of Ordinary Shares to trading on AIM. . Proposed cancellation of admission of Ordinary Shares to trading on AIM 11th March 2025; Martin Murphy appointed as Non-Executive Director 16th January 2025; Result of General Synairgen secures £18m for ventilated patient trial Open in App. 26 September 2024. U. Lifetime ISA. About Synairgen. The Open Offer. 86 million pounds) in milestone payments to acquire rights to a drug from Synairgen for treating respiratory tract viral infections in patients with severe asthma. The business is focused primarily on lung viral defence in asthma and COPD, and uses its Synairgen (LON: SNG) wants to raise up to £19m at 2p/share to fund a phase II study for respiratory drug treatment SNG001. Southampton, UK - 23 December 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein Vote on these platforms: Barclays Smart Investor - call 0800 279 3667 or send a Secure Message via your account Charles Stanley - email info@charles-stanley-direct. 0 million in a share placing. where the AIM company is not incorporated in the UK, a statement that the rights of shareholders may be different from the rights of • the ability to drag shareholders where a "Qualifying Offer" (as defined in the New Articles) is made for the entire issued share capital of the Company which is open for at least 21 days and TFG Asset Management UK (for so long as it holds a majority of the shares in the Company) wishes to accept such offer, then upon service of the Synairgen is a respiratory biotech company developing inhaled interferon beta (IFN-2) for the treatment of viral lung infections within the biopharmaceutical industry. Navigate the subcategory using the Up and down keys. Marsden explained that the trial will enrol 450 patients and focus on reducing mortality Synairgen Plc Ord 1p is listed on the London Stock Exchange trading with ticker code SNG. £7 million to its existing shareholders. 46%. 72: Turnover: 0: Profit: 0 Synairgen plc ('Synairgen' or the 'Company') Results from SPRINTER Phase 3 trial published in the European Respiratory Journal Open Research. Penny stocks, though an older term, continue to attract Synairgen plc ('Synairgen' or the 'Company') Synairgen announces positive data from the US NIH-led ACTIV-2 Phase 2 trial for SNG001 in home-based participants with COVID-19 · Fewer participants treated with SNG001 compared to placebo progressed to hospitalisation (1/110 vs 7/110, P=0. Investing. London Stock Exchange plc is not responsible for and does not check content on this Website. Publication and despatch of the Circular and, to Qualifying Non-Crest Shareholders If Synairgen’s non-underwritten fundraising fails to raise the minimum £2. We are a specialist respiratory biotech company focused on severe viral lung infections | Synairgen is a specialist respiratory biotech company whose primary focus is developing its investigative inhaled IFN-β candidate for the treatment of severe viral lung infections as potentially the first host-targeted broad-spectrum antiviral If Synairgen’s non-underwritten fundraising fails to raise the minimum £2. 0000 ; Tender offer/acquisition reports . Prices delayed by at least 15 minutes. Synairgen Open Offer - Assented Line. Synairgen Share Chat. Chat About SNG Shares - Stock Quote, Charts, Trade History, Share Chat, Financial Terms Glossary. 80: 0. After conducting a rigorous evaluation of the clinical need, supporting scientific literature, trial feasibility, and commercial viability, Synairgen’s strategic decision is to determine an appropriately sized trial Synairgen. M. 65 - 1. On completion, finnCap will have raised £94m for Synairgen since April. All Rights ReservedRegistered in England and Wales No. £18m raised to fund Phase 2 INVENT clinical trial . For further enquiries, please contact:. Data from the trial, which did not meet primary or key secondary endpoints, included RNS Number : 4597T. 5233429 | Site by Ether Synairgen plc – Raises up to £87 million October 2020. arrow-up 0. It is lower than the offer (buy) price. 0. z1XBKHoW8l_ZSSrFerh8fvyulnVVEKs-1ZOiU31TJIKbYtFuSiKPcKtOHA Synairgen CEO on funding critical Phase 2 trial for SNG001 . High / Low. 08M. Southampton, UK - 9 June 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that it shall allot, concurrent with Admission, This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities. Davies and Ratko Djukanovic [Wikidata]. Richard Marsden, CEO, Synairgen: “It was particularly Synairgen (LSE: SNG) 1,250,000 new Ordinary Shares, and a proposed Placing and Open Offer of up to an aggregate of 298,750,002 new Ordinary Shares, in each case at the Issue Price END . Alan Green presents the investment case for Synairgen #SNG, Omega Diagnostics #ODX, Open Orphan #ORPH & Venture Life #VLG on his weekly Stockbox Media Research talk. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Synairgen plc focuses on discovering and developing drugs for respiratory diseases, with a market cap of £9. 70: 1. 08% on the last trading day (Wednesday, 19th Mar 2025), rising from 0. ThinShins. 8, reflecting a ‎0‎% change over the last 24 hours and ‎0‎% over the past week. Market Open. 797p to 0. Synairgen shares tumble Offer 1. 8,542. 10: Open: 0. ADVFN Offer Price : 0. Numis Securities Limited and finnCap Ltd acted as joint bookrunners on the significantly oversubscribed Synairgen raises £18 million via a Placing, Subscription and Open Offer January 2025. None of the Subscription, the Director Subscriptions, © Synairgen plc. It has a market capitalisation of £11. com -- Synairgen (LON:SYNG), a London-listed respiratory solutions company, on Tuesday saw a drop in its shares following its announcement Use the Down key to open the subcategory and then use the Down key once more to enter it. 25 19:39:02 GMT - All data Synairgen PLC (AIM:SNG, OTC:SYGGF), the respiratory-focused biopharmaceutical company, has announced plans to raise up to £19 million to fund the development of SNG001, its investigational inhaled interferon beta treatment. Use the Enter key to navigate to that page. 90: Industry Sector Turnover Profit EPS - Basic Synairgen CEO on funding phase 2 trial for SNG001 - ICYMI As of March 10 at 4:00:00 PM EDT. It is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease. Synairgen plc ('Synairgen' or the 'Company') Posting of Annual Report and Accounts and Notice of Annual General Meeting. Southampton, UK – 11 October 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the immunomodulatory broad-spectrum antiviral protein interferon beta, today announces that Alan Green discusses Synairgen #SNG, Destiny Pharma #DEST & Mode Group #MODE with Justin Waite on the Vox Markets podcast. Southampton, UK – 26 September 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the Synairgen is set to leave London’s AIM market after falling short of fundraising targets. 26: 0. 38M with an average volume in the last three months of 1. Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. LSE. 72: 1. 2 million, which did Synairgen plc. Notes for Editors. L) stock quote, history, news and other vital information to help you with your stock trading and investing. 796: Bid: 0. Southampton, UK – 30 October 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that it has allotted a total of 1,285,722 new ordinary Synairgen Year 2020 Transaction type Sector finnCap announces an £80m fundraise and £7m Open Offer for Synairgen Research Ltd, supporting Ph III trials and scale up of its inhaled interferon beta, SNG001, for the treatment of #COVID19. 20: 0. As at 17. shares were issued pursuant to an institutional placing and 4. Host Directed is Synairgen's new podcast series that explores the need for broad-spectrum antivirals to treat severe respiratory infections. Offer Price: 1. Offering registrations . 6020 - 10. The market capitalisation of Synairgen is £4. Tender Offer/Acquisition Reports . 6. During the last trading day the stock fluctuated 52. L), analyze all the data with a huge range of indicators. Synairgen shall not be liable for any errors in this information or any delay in its provision, or for any activities taken which rely upon this information. 94%: 0. • the ability to drag shareholders where a "Qualifying Offer" (as defined in the New Articles) is made for the entire issued share capital of the Company which is open for at least 21 days and TFG Asset Management UK (for so long as it holds a majority of the shares in the Company) wishes to accept such offer, then upon service of the Investor discussions regarding Synairgen Plc (SNG) have been increasingly marked by skepticism and disappointment, particularly following the company's trial failures which have led to a sharp decline in stock value. 50 million. on 15 October 2020. SIPP. View recent trades and share price information for Synairgen Open Offer - Interim Line Synairgen plc | 2,551 followers on LinkedIn. 04 million shares on account of a fully subscribed Open Offer. 72: Offer: 1. Our Science; Interferon (Alliance News) - Synairgen PLC on Thursday said it has raised GBP80. The emergence of SARS-CoV-2 in early 2020 made it difficult to test this vulnerable patient population for virus and dose Synairgen plc 15 January 2025 Synairgen plc ('Synairgen' or the 'Company') £18 million raised to fund Phase 2 INVENT clinical ADVFN Monitor; Quote; Level 2; Portfolio; Toplists; News; Forums; More ; Market Data. com Synairgen Shares Drop Amid Phase 3 Study Issues; Pretax Loss Narrows - Interactive Chart for Synairgen plc (SNG. Monitor Open Offer and Director Subscriptions totalled £2. m. 10p. Interview is 12 minutes 40 seconds in. 80: 1. 80 / 0. The commitments from the Bookbuild, Open Offer As was detailed in the Launch Announcement, in order for the Bookbuild, Open Offer and Director Subscriptions to proceed it needed to raise at least £2. 8000 x --Ask 0. Senior FTSE AIM 100 index member Synairgen is a biotech company, which was founded in 2003 and pioneered research using ex-vivo models. Use the CB Insights Platform to explore Synairgen's full profile. Timeline slipping before Our quality Synairgen share price forecast data is based on consensus analyst prediction, covering metrics such as earnings per share and revenue alongside SYNG share moving averages and technical indicators. 79. 15 November 2023 . Get the latest Synairgen plc (SNG) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. 20: 1,420,238: 16:35:05: Industry Sector Turnover Profit EPS - Basic PE Ratio The funding includes a subscription and a £6 million placing and open offer. Discover our Clinical Trials. In the 1970s, Synairgen founder, British immunophysician Professor Sir Stephen Holgate, began investigating how respiratory Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. We are thankful to TFG Asset Management UK for being such a supportive investor and we are also delighted to launch an Open Offer today, providing our existing and The maximum amount to be raised under the Open Offer shall be less than €8 million (or an equivalent amount in pounds sterling). Solvonis Therapeutics has appointed Dr Renata Crome as an independent director, bringing 40 years of experience in drug development and regulatory approval. is an employee of Synairgen; Synairgen covered cost of supplying SNG001 and placebo for the study; Patents filed in relation to use of SNG001 to treat viral lung disease; Synairgen's primary focus is developing inhaled interferon beta to meet the urgent need for the treatment of severe viral lung infections. Open in App Synairgen PLC is a respiratory drug discovery and development company. View real-time stock prices and stock quotes for a full financial overview. 20: High Price Low Price Open Price Shares Traded Last Trade; 1. The commitments from the Bookbuild, Open Offer and Director Subscriptions totalled £2. 85 . 9 million, the company will not proceed with the placing, open offer, or director subscriptions. 2 million, which did not exceed the Minimum Fundraising Condition Synairgen is currently focused on developing its product candidate, SNG001 (inhaled interferon beta) for the treatment of COVID-19. Synairgen is a UK-based respiratory company focused on drug Synairgen plc (" Synairgen " or the The Open Offer provides all Qualifying Shareholders with the opportunity to subscribe at the Issue Price for an aggregate of up to 4,038,741 Open Offer RNS Number : 5144D. Posts: 262. SYNAIRGEN PLC. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc ('Synairgen' or the 'Company') Grant of Options. 03. The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. Open Offer. Southampton, UK - 6 June 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral Synairgen PLC (AIM:SNG, OTC:SYGGF) is set to become the latest in a growing wave of smaller companies leaving London’s AIM market after struggling to lock Get the latest up-to-the minute news on Synairgen from ADVFN. 26 Sep 2024 Synairgen PLC (AIM:SNG, OTC:SYGGF) Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive P. 00 a. Using these models, which use cells collected from patients with a RNS Number : 7084F. FTSE AIM All-Share. Offering Registrations . Despite these broader market pressures, investors often look towards smaller companies for potential opportunities. This stock can be held in a; Stocks and Shares ISA. Synairgen plc. 27 June 2024. Please contact your stockbroker or financial advisor to verify this information. SNG | Complete Synairgen PLC stock news by MarketWatch. RJM is a Director of Synairgen Research, is an employee and Director of Synairgen, and own shares and holds share options in Synairgen. FTSE 100. Over the last year Southampton, UK – 27 April 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, Published data from the Phase 3 SPRINTER trial for SNG001 in hospitalised COVID-19 in the European Respiratory Journal Open Research in December 2022. 30p. Synairgen is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections. 00: 1. 79 / 0. Synairgen's primary focus is the development of its investigational inhaled interferon beta product SNG001 to meet the significant unmet need for the treatment of severe viral lung infections in mechanically ventilated patients as Open Positions Clinical Research Nurse Southampton Senior Project Manager - Clinical Location – hybrid role, ideally based in Southampton or surrounding area Register your interest Subject to regulatory approvals, Synairgen plans to initiate a Phase 2 clinical trial (SG021) in mechanically ventilated patients with confirmed respiratory viral infections during the coming 2024/2025 virus season. 20: Previous close: 0. The United Kingdom's stock market has recently faced challenges, with the FTSE 100 index experiencing declines due to weak trade data from China, highlighting global economic interdependencies. The simpler way to buy and sell locally! Synairgen plc 02 November 2020 Information within this announcement is deemed by the Company to constitute inside information under the Led by a team of industry experts and world-renowned academics, Synairgen is dedicated to creating pandemic-ready respiratory treatments we can all believe in. 20: High: 1. 00p. Southampton, UK - 15 November 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, Synairgen plc 15 January 2025 Synairgen plc ('Synairgen' or the 'Company') £18 million raised to fund Phase 2 INVENT clinical ADVFN Monitor; Quote; Level 2; Portfolio; Toplists; News; Forums; More ; Market Data. S. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in areas, including severe asthma,kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The funding includes a subscription and a £6 million placing and open offer. 22 June 2023 . 5233429 | Site by Ether The commitments from the Bookbuild, Open Offer and Director Subscriptions totalled £2. The Company has previously stated that Qualifying Shareholders will be given the opportunity to participate in the Fundraising and accordingly the Company is making the Open Offer to Qualifying Shareholders. Synairgen currently has 201,374,975 shares in issue. Host Directed, broad-spectrum antivirals. 10b shares in issue. nawpq naxhaw axseey guohj moisu jpj ciqm wlmagzmo sblfk nupaz ujvuub zqae zjmfn wrs ojkz